This new evidence raises worries about the spread of AGS, particularly in regions like Long Island, where ticks are a growing ...

The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in ...

This new evidence raises worries about the spread of AGS, particularly in regions like Long Island, where ticks are a growing ...

Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...

Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

Aquestive Therapeutics leverages its PharmFilm technology to develop innovative oral drug delivery systems. Find out why I'm neutral on AQST stock.

Good day, and welcome to ARS Pharmaceuticals fourth quarter and full year 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I would now like ...

This past week, my Motion 518: Expanding Availability of Epinephrine Auto-Injectors was successfully passed in Alberta’s ...

The maker of a new prescription drug product for people with life-threatening allergies is using copayment coupons to build ...

Symptoms that warrant immediate emergency care, from chest pain to severe allergic reactions, and when urgent care or ...

Eric Karas, Chief Commercial Officer, outlined the company's multi-pronged strategy to increase neffy adoption, focusing on education, payer coverage, and patient awareness. He noted that neffy ...

ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and strategic advancements in global commercialization, despite challenges in market adoption.